(NASDAQ: ARTV) Artiva Biotherapeutics's forecast annual revenue growth rate of 756.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Artiva Biotherapeutics's revenue in 2025 is $251,000.On average, 1 Wall Street analysts forecast ARTV's revenue for 2028 to be $338,160,092, with the lowest ARTV revenue forecast at $338,160,092, and the highest ARTV revenue forecast at $338,160,092. On average, 1 Wall Street analysts forecast ARTV's revenue for 2029 to be $1,855,251,512, with the lowest ARTV revenue forecast at $1,855,251,512, and the highest ARTV revenue forecast at $1,855,251,512.
In 2030, ARTV is forecast to generate $3,935,374,612 in revenue, with the lowest revenue forecast at $3,935,374,612 and the highest revenue forecast at $3,935,374,612.